C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
FFNTF Equity

4Front Ventures

OTCMKTS · FFNTF

$0.00
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
38/100 composite
Fundamentals31
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

4Front Ventures lands at 38 on the CIN composite, a Neutral outcome with conviction of 3/5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 49 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.

The observable inputs tell a straightforward story: reported revenue growth of -25.5 percent year over year, an operating margin of -38.4 percent, a jurisdictional posture reading of 50. Every figure is auditable in the accompanying pillar table. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets 4Front Ventures be lined up against the US operator peer set on identical inputs, with refresh cadence tied directly to primary-source ingest.

Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 49. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Neutral conclusion.

Scored: 2026-07-14Valid through: 2026-08-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
CEO
Leo Go***r
SEC CIK
0001783875
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$0.0M
Enterprise value
$212.9M
Price to book
3.31
EV / EBITDA
-258.86
Revenue (TTM)
$75.6M
Gross profit (TTM)
$26.9M
EBITDA
$-17.0M
Operating margin
-38.4%
Profit margin
-48.1%
Rev growth YoY
-25.5%
Return on equity
-182.7%
Return on assets
-5.1%
EPS (TTM)
$-0.11
Wall St. target price
$2.37
Shares outstanding
913.9M
Insider ownership
51.1%
Institutional ownership
6.7%
Beta
0.17
Full-time employees
374
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for 4Front Ventures (FFNTF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for 4Front Ventures (FFNTF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for FFNTF are maintained by Cannabis Investor News and refreshed throughout the trading day.